ArticleAnnals of epidemiology2026
Early adherence predicts treatment outcomes and mortality in people living with HIV and multidrug-resistant tuberculosis.
Article in Annals of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
purposeTreatment success for RR/MDR-TB remains suboptimal, particularly among people living with HIV. Electronic dose monitors support adherence, but strategies to act on these data are limited. We hypothesized that early adherence to bedaquiline predicts treatment outcomes and could guide individualized interventions.
methodsWe prospectively enrolled adults with RR/MDR-TB and HIV initiating bedaquiline-containing regimens in KwaZulu-Natal, South Africa. Adherence was measured using real-time electronic dose monitors. Weekly adherence data through week 24 trained time-aware XGBoost models to predict end-of-treatment outcomes, and latent class growth analysis (LCGA) at the earliest predictive time point identified distinct adherence trajectories.
resultsAmong 282 participants, model performance improved over time, achieving good discrimination by week 4 (AUC > 0.80), predictive of subsequent adherence. LCGA using 4-week data identified three adherence trajectories: high, moderate-stable, and early-declining. Favorable outcomes were lowest in the early-declining group (55% vs. 77% and 76%), which also had the highest mortality (36% vs. 12% and 12%). Cox models confirmed a higher risk of unfavorable outcomes among early decliners.
conclusionAdherence in the first four weeks of bedaquiline therapy provides a powerful, early signal of treatment outcomes. Real-time adherence monitoring could enable risk stratification and tailored interventions to improve RR/MDR-TB and HIV care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.